Search

Your search keyword '"F.Y. Feng"' showing total 42 results
Start Over Author "F.Y. Feng" Journal international journal of radiation oncology*biology*physics
42 results on '"F.Y. Feng"'

2. Prostate-Specific Membrane Antigen PET Response Associates with Metastasis-Free Survival Following Stereotactic Ablative Radiation Therapy in Oligometastatic Castration-Sensitive Prostate Cancer

Author

P. Sutera, M.P. Deek, O.C. Guler, P. Hurmuz, M. Reyhan, S. Rowe, W.T. Hrinivich, L. Ren, D. Song, A.P. Kiess, E. Oymak, K. Pienta, M.G. Pomper, F.Y. Feng, G. Ozyigit, P.T. Tran, R. Phillips, and C. Onal

Subjects
Cancer Research, Radiation, Oncology, Radiology, Nuclear Medicine and imaging
Published
2022
Full Text
View/download PDF

3. Prognostic and Predictive Performance of a 24-Gene Post-Operative Radiation Therapy Outcomes Score (PORTOS) in a Phase 3 Randomized Trial of Dose-Intensified Salvage Radiotherapy after Radical Prostatectomy (SAKK 09/10)

Author

A. Dal Pra, D.R. Zwahlen, V.Y. Liu, S. Hayoz, D.E. Spratt, E. Davicioni, Y. Liu, J.A. Proudfoot, C. Schär, T. Hölscher, P. Gut, B. Polat, G. Hildebrandt, A.C. Mueller, L. Plasswilm, F.Y. Feng, A. Pollack, G. Thalmann, D.M. Aebersold, and P. Ghadjar

Subjects
Cancer Research, Radiation, Oncology, Radiology, Nuclear Medicine and imaging
Published
2022
Full Text
View/download PDF

4. Challenges and Solutions during the COVID Pandemic for Patient Retention and Physician Engagement in the Phase 3 ATLAS Study of Apalutamide Added to Androgen Deprivation Therapy (ADT) in High-Risk Localized or Locally Advanced Prostate Cancer (HRLPC)

Author

H.M. Sandler, N. Shore, D. Dearnaley, S.J. Freedland, M.R. Smith, R. Rosales, S.D. Brookman-May, A.P. Dicker, M.R. McKenzie, A. Bossi, A. Widmark, T. Wiegel, J. Martin, B. Miladinovic, F. Lefresne, M. Ciprotti, S.A. McCarthy, S.D. Mundle, B.F. Tombal, and F.Y. Feng

Subjects
Cancer Research, Radiation, Oncology, Radiology, Nuclear Medicine and imaging
Published
2022
Full Text
View/download PDF

5. INTACT (S/N1806): Phase III Randomized Trial of Concurrent Chemoradiotherapy with or without Atezolizumab in Localized Muscle Invasive Bladder Cancer—Toxicity Update on First 213 Patients

Author

P. Singh, J.A. Efstathiou, M. Plets, S.G. Jhavar, S. Delacroix, A. Tripathi, A. Gupta, S. Sachdev, A. Jani, A.N. Kirschner, C. Tangen, R. Bangs, M. Joshi, B.A. Costello, I.L. Thompson, F.Y. Feng, and S. Lerner

Subjects
Cancer Research, Radiation, Oncology, Radiology, Nuclear Medicine and imaging
Published
2022
Full Text
View/download PDF

6. Prostate Cancer Risk Stratification in NRG Oncology Phase III Randomized Trials Using Multi-Modal Deep Learning with Digital Histopathology

Author

J.D. Tward, J. Zhang, A. Esteva, O. Mohamad, D. van der Wal, J. Simko, S. DeVries, H.C. Huang, E.M. Schaeffer, T.M. Morgan, H.A. Campbell, J. Monson, J. Wallace, M.J. Ferguson, J.P. Bahary, H.M. Sandler, D.E. Spratt, J. Rodgers, F.Y. Feng, and P.T. Tran

Subjects
Cancer Research, Radiation, Oncology, Radiology, Nuclear Medicine and imaging
Published
2022
Full Text
View/download PDF

7. Phase II Randomized Study of Salvage Radiation Therapy (SRT) plus Enzalutamide or Blinded Placebo for High-Risk PSA-Recurrent Prostate Cancer after Radical Prostatectomy: The SALV-ENZA Trial

Author

P.T. Tran, K. Lowe, H. Wang, H.L. Tsai, D. Song, A.Y. Hung, J.W.D. Hearn, S.R. Miller, T.L. Lotan, T.L. DeWeese, M.D. Orton, C. Deville Jr, S. Liauw, E. Heath, S.C. Greco, N.B. Desai, D.E. Spratt, F.Y. Feng, T. Beer, and E. Antonarakis

Subjects
Cancer Research, Radiation, Oncology, Radiology, Nuclear Medicine and imaging
Published
2022
Full Text
View/download PDF

10. National Trends and Predictors of Androgen Deprivation Therapy Use in Low-Risk Prostate Cancer

Author

Karen E. Hoffman, Peter F. Orio, David D. Yang, Martin T. King, Paul L. Nguyen, Vinayak Muralidhar, Marie E. Vastola, D.E. Spratt, F.Y. Feng, Shelby A. Labe, Michelle D. Nezolosky, Neil E. Martin, Brandon A. Mahal, Toni K. Choueiri, and Quoc-Dien Trinh

Subjects
Adult, Male, Risk, Oncology, Cancer Research, medicine.medical_specialty, Databases, Factual, medicine.medical_treatment, Brachytherapy, Cancer Care Facilities, Androgen deprivation therapy, 03 medical and health sciences, Prostate cancer, 0302 clinical medicine, Internal medicine, medicine, Humans, Radiology, Nuclear Medicine and imaging, 030212 general & internal medicine, Aged, Proportional Hazards Models, Aged, 80 and over, Prostatectomy, Gynecology, Academic Medical Centers, Radiation, Radiotherapy, business.industry, Proportional hazards model, Hazard ratio, Prostatic Neoplasms, Cancer, Androgen Antagonists, Community Health Centers, Odds ratio, Middle Aged, medicine.disease, National Cancer Institute (U.S.), United States, Confidence interval, Logistic Models, Cryotherapy, 030220 oncology & carcinogenesis, Neoplasm Grading, business
Abstract

Androgen deprivation therapy (ADT) is not recommended for low-risk prostate cancer because of its lack of benefit and potential for harm. We evaluated the incidence and predictors of ADT use in low-risk disease.Using the National Cancer Database, we identified 197,957 patients with low-risk prostate cancer (Gleason score of 3 + 3 = 6, prostate-specific antigen level10 ng/mL, and cT1-T2a) diagnosed from 2004 to 2012 with complete demographic and treatment information. We used multiple logistic regression to evaluate predictors of ADT use and Cox regression to examine its association with all-cause mortality.Overall ADT use decreased from 17.6% in 2004 to 3.5% in 2012. In 2012, 11.5% of low-risk brachytherapy patients and 7.6% of external beam radiation therapy patients received ADT. Among 82,352 irradiation-managed patients, predictors of ADT use included treatment in a community versus academic cancer program (adjusted odds ratio [AOR], 1.60; 95% confidence interval [CI], 1.50-1.71; P.001; incidence, 14.0% vs 6.0% in 2012); treatment in the South (AOR, 1.51), Midwest (AOR, 1.81), or Northeast (AOR, 1.90) versus West (P.001); and brachytherapy use versus external beam radiation therapy (AOR, 1.32; 95% CI, 1.27-1.37; P.001). Among 25,196 patients who did not receive local therapy, predictors of primary ADT use included a Charlson-Deyo comorbidity score of ≥2 versus 0 (AOR, 1.42; 95% CI, 1.06-1.91; P=.018); treatment in a community versus academic cancer program (AOR, 1.61; 95% CI, 1.37-1.90; P.001); and treatment in the South (AOR, 1.26), Midwest (AOR, 1.52), or Northeast (AOR, 1.28) versus West (P≤.008). Primary ADT use was associated with increased all-cause mortality in patients who did not receive local therapy (adjusted hazard ratio, 1.28; 95% CI, 1.14-1.43; P.001) after adjustment for age and comorbidity.ADT use in low-risk prostate cancer has declined nationally but may remain an issue of concern in certain populations and regions.

Published
2017
Full Text
View/download PDF

11. Metastasis-Free Survival, but Not Biochemical Failure, is a Strong Surrogate Endpoint for Overall Survival in Recurrent Prostate Cancer: Analysis of NRG Oncology/RTOG 9601

Author

William C. Jackson, Robert T. Dess, W. Seiferheld, William U. Shipley, Kenneth L. Zeitzer, H. Lukka, Zachary S. Zumsteg, Anthony L. Zietman, M.J. Schipper, D.E. Spratt, R.D. Lovett, Ming Tang, William A. Hall, Alexander Balogh, H.M. Sandler, Jason A. Efstathiou, Thomas M. Pisansky, Jean-Paul Bahary, and F.Y. Feng

Subjects
Oncology, Cancer Research, medicine.medical_specialty, Radiation, Surrogate endpoint, business.industry, Biochemical failure, Internal medicine, Metastasis free survival, medicine, Overall survival, Radiology, Nuclear Medicine and imaging, Recurrent prostate cancer, business
Published
2020
Full Text
View/download PDF

12. The Influence of the Pretreatment Host Immune State on Response to Radiation Therapy in High Risk Adenocarcinoma of the Prostate: A Validation Study from NRG Oncology/RTOG 0521 (Updated)

Author

Mitual Amin, Colleen A. Lawton, B.L. Danielson, Carmen Bergom, James A. Purdy, Theodore Karrison, Oliver Sartor, Seth A. Rosenthal, J.M. Michalski, H.M. Sandler, Paul Nguyen, Leonard G. Gomella, F.Y. Feng, William A. Hall, Ashesh B. Jani, Mark Garzotto, W.R. Lee, Jeffry P. Simko, J. Moore, and Elizabeth Gore

Subjects
Oncology, Cancer Research, Validation study, medicine.medical_specialty, Radiation, business.industry, medicine.medical_treatment, medicine.disease, Radiation therapy, Immune state, medicine.anatomical_structure, Prostate, Internal medicine, medicine, Adenocarcinoma, Radiology, Nuclear Medicine and imaging, business, Host (network)
Published
2020
Full Text
View/download PDF

13. Evaluating the Evidence to Support Clinical Use of the 22-Gene Genomic Classifier (Decipher) in Prostate Cancer

Author

A. Dal Pra, Neil K. Jairath, D.E. Spratt, Rohit Mehra, William C. Jackson, Robert T. Dess, Todd M. Morgan, and F.Y. Feng

Subjects
Cancer Research, Prostate cancer, Radiation, Oncology, business.industry, medicine, DECIPHER, Radiology, Nuclear Medicine and imaging, Computational biology, medicine.disease, business, Gene, Classifier (UML)
Published
2020
Full Text
View/download PDF

14. NRG Oncology Updated International Consensus Atlas on Pelvic Lymph Node Volumes for Intact and Post-Operative Prostate Cancer

Author

W.A. Hall, E.S. Paulson, B.J. Davis, D.E. Spratt, D. Dearnaley, J.A. Efstathiou, A. Jani, M.K. Buyyounouski, T.M. Pisansky, P.T. Tran, R.C. Chen, F. Cury, J.M. Michalski, S.A. Rosenthal, B.F. Koontz, A.C. Wong, A. Tree, P.L. Nguyen, F.Y. Feng, H.M. Sandler, and C.A.F. Lawton

Subjects
Cancer Research, Radiation, Oncology, Radiology, Nuclear Medicine and imaging
Published
2020
Full Text
View/download PDF

15. Effect Of Hormone Therapy Within Risk Groups Defined By Generalized Competing Event Model: Ancillary Analysis Of NRG Oncology’s RTOG 9408

Author

K.N. Choi, Siraj Husain, Stephanie L. Pugh, M. Roach, M. Morginstin, Tyler J. Nelson, Eric M. Horwitz, Alan C. Hartford, Jean-Paul Bahary, Shawn Malone, Christopher U. Jones, Kaveh Zakeri, J.M. Michalski, Matthew Parliament, F.Y. Feng, Thomas M. Pisansky, Mark V. Mishra, Luis Souhami, Elizabeth Gore, and Loren K. Mell

Subjects
Oncology, Cancer Research, medicine.medical_specialty, Radiation, business.industry, medicine.medical_treatment, Event model, Risk groups, Internal medicine, Medicine, Radiology, Nuclear Medicine and imaging, Hormone therapy, business
Published
2020
Full Text
View/download PDF

16. The Impact of Persistently Elevated PSA after Prostatectomy in Men with Recurrent Prostate Cancer in NRG Oncology/RTOG 9601

Author

Yi Sun, William U. Shipley, H.M. Sandler, Paul Nguyen, L.A. Gharzai, Zachary S. Zumsteg, Jason A. Efstathiou, William A. Hall, Brandon A. Mahal, Anthony L. Zietman, D.E. Spratt, A.U. Kishan, William C. Jackson, Robert T. Dess, M.J. Schipper, S. Birer, J.M. Michalski, F.Y. Feng, and Todd M. Morgan

Subjects
Oncology, Cancer Research, medicine.medical_specialty, Radiation, business.industry, Prostatectomy, medicine.medical_treatment, Elevated PSA, Internal medicine, medicine, Radiology, Nuclear Medicine and imaging, Recurrent prostate cancer, business
Published
2020
Full Text
View/download PDF

17. Comprehensive Analysis of Candidate Surrogate Endpoints in Localized Prostate Cancer: Analysis of 59 Randomized Trials

Author

F.Y. Feng, M.J. Schipper, A.U. Kishan, E. Jaworski, L.A. Gharzai, S. Birer, D.E. Spratt, Neil K. Jairath, David G. Wallington, Todd M. Morgan, Brandon A. Mahal, Gavin P. Jones, Ralph Jiang, Robert T. Dess, H.M. Sandler, Matthew R. McFarlane, and William C. Jackson

Subjects
Oncology, Cancer Research, medicine.medical_specialty, Radiation, business.industry, Surrogate endpoint, medicine.disease, law.invention, Prostate cancer, Randomized controlled trial, law, Internal medicine, medicine, Radiology, Nuclear Medicine and imaging, business
Published
2020
Full Text
View/download PDF

18. Impact Of Sequencing Of Androgen Receptor-Signaling Inhibition (ARSI) And Ionizing Radiotherapy (RT) In Prostate Cancer: Importance Of Homologous Recombination (HR) Disruption

Author

Colleen A. Lawton, C. Zhang, Robert T. Dess, Shawn Malone, Corey Speers, H.M. Sandler, Arul M. Chinnaiyan, Joshi J. Alumkal, William C. Jackson, Steven G. Allen, Rohit Mehra, Yi Sun, M. Roach, D.E. Spratt, Subrata Shyam Roy, D.R. Wahl, and F.Y. Feng

Subjects
Cancer Research, Radiation, business.industry, medicine.medical_treatment, medicine.disease, Ionizing radiation, Androgen receptor, Radiation therapy, Prostate cancer, Oncology, Cancer research, medicine, Radiology, Nuclear Medicine and imaging, Homologous recombination, business
Published
2020
Full Text
View/download PDF

19. Short-Term Adjuvant versus Neoadjuvant Hormone Therapy in Localized Prostate Cancer: A Pooled Individual Patient Analysis of Two Randomized Phase 3 Trials

Author

William U. Shipley, M. Roach, William C. Jackson, Libni Eapen, W.R. Lee, Colleen A. Lawton, Scott C. Morgan, D.E. Spratt, Shawn Malone, Sujoy B. Roy, Yutao Sun, Julia Craig, Robert T. Dess, H.M. Sandler, Julia Malone, Scott Grimes, M.J. Schipper, J.M. Michalski, F.Y. Feng, and Thomas M. Pisansky

Subjects
Oncology, Cancer Research, medicine.medical_specialty, Radiation, business.industry, medicine.medical_treatment, medicine.disease, Term (time), Prostate cancer, Internal medicine, medicine, Radiology, Nuclear Medicine and imaging, Hormone therapy, business, Adjuvant
Published
2020
Full Text
View/download PDF

20. Transcriptomic Heterogeneity in Pathological Grade Group 5 Prostate Cancer: Implications for Biomarker Discovery

Author

Robert Jeffrey Karnes, Tristan Grogan, Tahmineh Romero, Nicholas G. Nickols, E.A. Klein, Tamara L. Lotan, F.Y. Feng, A.U. Kishan, Phuoc T. Tran, D.E. Spratt, R.E. Reiter, Paul Nguyen, Robert B. Den, Paul C. Boutros, M. Rettig, Mohammed Alshalalfa, Edward M. Schaeffer, E. Davicioni, S.J. Freedland, and Joanne B. Weidhaas

Subjects
Oncology, Cancer Research, medicine.medical_specialty, Radiation, business.industry, medicine.disease, Transcriptome, Prostate cancer, Internal medicine, Medicine, Radiology, Nuclear Medicine and imaging, Biomarker discovery, business, Pathological
Published
2019
Full Text
View/download PDF

21. Stereotactic Body Radiotherapy for Localized Prostate Cancer: A Systematic Review and Meta-Analysis of Over 6,000 Patients Treated On Prospective Studies

Author

W.C. Jackson, J. Silva, H.E. Hartman, R.T. Dess, W.H. Beeler, L. Jaworski, P.D. Soni, B.A. Mahal, A.U. Kishan, R. Mehra, J.W.D. Hearn, T.M. Morgan, S. Kaffenberger, P.L. Nguyen, N.B. Desai, F.Y. Feng, Z.S. Zumsteg, and D.E. Spratt

Subjects
Cancer Research, Radiation, Oncology, Radiology, Nuclear Medicine and imaging
Published
2019
Full Text
View/download PDF

22. Prostate Cancer-Specific Mortality Following Salvage Post-Prostatectomy Radiation Therapy: A Competition Between Age and Time to Biochemical Failure

Author

Vasu Tumati, S. Jolly, Simpa S. Salami, William C. Jackson, Neil Desai, Krithika Suresh, Todd M. Morgan, Rohit Mehra, M.J. Schipper, Arvin K. George, Brent K. Hollenbeck, F.Y. Feng, Robert T. Dess, Samuel D. Kaffenberger, Payal D. Soni, Zachary S. Zumsteg, Jason W.D. Hearn, Raquibul Hannan, D.E. Spratt, and Shuang G. Zhao

Subjects
Oncology, Cancer Research, medicine.medical_specialty, Radiation, business.industry, media_common.quotation_subject, medicine.medical_treatment, Biochemical failure, Specific mortality, medicine.disease, Competition (biology), Radiation therapy, Prostate cancer, Internal medicine, medicine, Radiology, Nuclear Medicine and imaging, business, Post prostatectomy, media_common
Published
2018
Full Text
View/download PDF

23. Development and Validation of Xenograft-Based Platform-Independent Gene Signatures That Predict Response to Alkylating Chemotherapy, Radiation, and Combination Therapy in Glioblastoma

Author

Corey Speers, J. Eckel-Passow, Menggang Yu, Minsun Kim, Jann N. Sarkaria, S.L. Chang, Theodore S. Lawrence, Shuang G. Zhao, Paul A. Decker, D.E. Spratt, Brett L. Carlson, A.C. Tuma, D.R. Wahl, and F.Y. Feng

Subjects
Cancer Research, Chemotherapy, Platform independent, Radiation, Combination therapy, business.industry, medicine.medical_treatment, medicine.disease, Oncology, Cancer research, medicine, Radiology, Nuclear Medicine and imaging, business, Gene, Glioblastoma
Published
2018
Full Text
View/download PDF

24. 68Ga-PSMA-11 PET-Based Prostate Cancer Lymph Node Atlas Reveals Patterns of Potential Geographic Miss in Consensus Pelvic Nodal Contours

Author

F.Y. Feng, S. Sinha, P. Carroll, H. Vasudevan, Anthony C. Wong, Katelyn Hasse, A. Witztum, and T. Hope

Subjects
Cancer Research, medicine.medical_specialty, Radiation, business.industry, Atlas (topology), medicine.disease, 68Ga-PSMA-11, Prostate cancer, medicine.anatomical_structure, Oncology, Medicine, Radiology, Nuclear Medicine and imaging, Radiology, business, NODAL, Lymph node
Published
2019
Full Text
View/download PDF

25. Associations of Stromal Infiltration with Prognosis and Response to Postoperative Radiotherapy in Prostate Cancer

Author

Timothy R. Rebbeck, Paul Nguyen, Robert Jeffrey Karnes, Tamara L. Lotan, Himisha Beltran, S.Y. Ku, Mohammed Alshalalfa, Edward M. Schaeffer, Brandon A. Mahal, William S. Chen, Shuang G. Zhao, E. Davicioni, and F.Y. Feng

Subjects
Cancer Research, Pathology, medicine.medical_specialty, Radiation, Stromal cell, business.industry, Postoperative radiotherapy, medicine.disease, Prostate cancer, Oncology, medicine, Radiology, Nuclear Medicine and imaging, business, Infiltration (medical)
Published
2019
Full Text
View/download PDF

26. Comparison of Population-Based Observational Studies to Randomized Controlled Trials in Prostate Cancer

Author

Whitney H. Beeler, William C. Jackson, Payal D. Soni, Steven G. Allen, F.Y. Feng, M.J. Schipper, D.E. Spratt, L.A. Gharzai, Holly E. Hartman, and Robert T. Dess

Subjects
Oncology, Cancer Research, medicine.medical_specialty, Radiation, business.industry, Population based, medicine.disease, law.invention, Prostate cancer, Randomized controlled trial, law, Internal medicine, medicine, Radiology, Nuclear Medicine and imaging, Observational study, business
Published
2019
Full Text
View/download PDF

28. Novel Associations Between the Immune Landscape of Prostate Cancer and Postoperative Radiation Response

Author

F.Y. Feng, Rajdeep Das, A.J. Chang, E.A. Klein, M. Sjostrom, Shuang G. Zhao, L. Fong, Robert Jeffrey Karnes, E. Davicioni, Edward M. Schaeffer, Daniel E. Spratt, Steven L. Chang, Ashley E. Ross, Robert B. Den, N. Erho, Paul Nguyen, S.J. Freedland, Melody J. Xu, and J. Lehrer

Subjects
Oncology, Cancer Research, medicine.medical_specialty, Radiation, business.industry, Postoperative radiation, medicine.disease, Prostate cancer, Immune system, Internal medicine, medicine, Radiology, Nuclear Medicine and imaging, business
Published
2017
Full Text
View/download PDF

30. Development and Validation of Genomic Tools to Predict Extraprostatic Extension of Prostate Cancer, Opportunities for Personalizing Treatment

Author

Robert T. Dess, Paul Nguyen, Robert Jeffrey Karnes, Colleen A. Lawton, Anthony C. Wong, Nick Fishbane, Melody J. Xu, Peter R. Carroll, William A. Hall, S. Liu, Brandon A. Mahal, D.E. Spratt, E. Davicioni, Robert B. Den, Edward M. Schaeffer, William C. Jackson, and F.Y. Feng

Subjects
Oncology, Cancer Research, medicine.medical_specialty, Radiation, business.industry, 030232 urology & nephrology, medicine.disease, 03 medical and health sciences, Prostate cancer, 0302 clinical medicine, 030220 oncology & carcinogenesis, Internal medicine, medicine, Radiology, Nuclear Medicine and imaging, Extraprostatic extension, business
Published
2018
Full Text
View/download PDF

31. Genomic Validation of Three-Tiered Sub-Classification of High-Risk Prostate Cancer

Author

Paul Nguyen, Kasra Yousefi, F.Y. Feng, Qiqi Wang, Jingbin Zhang, Voleak Choeurng, Vinayak Muralidhar, D.E. Spratt, and E. Davicioni

Subjects
Oncology, Cancer Research, medicine.medical_specialty, Prostate cancer, Radiation, business.industry, Internal medicine, medicine, Radiology, Nuclear Medicine and imaging, medicine.disease, business, Sub classification
Published
2018
Full Text
View/download PDF

32. Androgen Receptor Activity and Radiotherapeutic Sensitivity in African-American Men with Prostate Cancer: A Large Scale Gene Expression Analysis and Meta-Analysis of RTOG Trials

Author

Payal D. Soni, Zachary S. Zumsteg, William U. Shipley, D.E. Spratt, Corey Speers, Brandon A. Mahal, Mohammed Alshalalfa, F.Y. Feng, E. Davicioni, M.J. Schipper, Holly E. Hartman, H.M. Sandler, M. Roach, Edward M. Schaeffer, Thomas M. Pisansky, Paul Nguyen, William C. Jackson, Shuang G. Zhao, Robert T. Dess, and Nick Fishbane

Subjects
Oncology, Cancer Research, medicine.medical_specialty, Radiation, business.industry, medicine.disease, 03 medical and health sciences, Prostate cancer, 0302 clinical medicine, 030220 oncology & carcinogenesis, Internal medicine, Meta-analysis, Gene expression, medicine, African american men, Radiology, Nuclear Medicine and imaging, 030212 general & internal medicine, business, Androgen receptor activity
Published
2018
Full Text
View/download PDF

33. Erectile Function After Stereotactic Body Radiation Therapy for Prostate Cancer: A Validated Model-Based Comparison to Nerve-Sparing Prostatectomy, Conventional Radiation Therapy, and Brachytherapy

Author

Sean P. Collins, Simeng Suy, M.J. Schipper, William C. Jackson, Robert T. Dess, Ahmed E. Abugharib, F.Y. Feng, Payal D. Soni, Rohit Mehra, Daniel A. Hamstra, Holly E. Hartman, and D.E. Spratt

Subjects
Cancer Research, medicine.medical_specialty, Radiation, business.industry, Stereotactic body radiation therapy, medicine.medical_treatment, Brachytherapy, Urology, medicine.disease, Radiation therapy, Nerve-Sparing Prostatectomy, Prostate cancer, Oncology, Medicine, Radiology, Nuclear Medicine and imaging, Radiology, business
Published
2017
Full Text
View/download PDF

34. Prostate Stereotactic Body Radiation Therapy: An Assessment of Modern Sexual Aid Utilization and Efficacy Following Definitive Treatment for Localized Prostate Cancer

Author

Theresa Devasia, Simeng Suy, F.Y. Feng, Sean P. Collins, William C. Jackson, M.J. Schipper, Robert T. Dess, Payal D. Soni, and D.E. Spratt

Subjects
Oncology, Cancer Research, medicine.medical_specialty, Radiation, business.industry, Stereotactic body radiation therapy, medicine.disease, Prostate cancer, medicine.anatomical_structure, Prostate, Internal medicine, Medicine, Radiology, Nuclear Medicine and imaging, business
Published
2017
Full Text
View/download PDF

35. Location of Recurrence by Gallium-68 PSMA PET Scan in Prostate Cancer Patients Eligible for Salvage Radiation Therapy

Author

Hao G. Nguyen, F.Y. Feng, Albert J. Chang, M. Roach, Lauren Boreta, Peter R. Carroll, Thomas A. Hope, Susan Y. Wu, Abraham J. Wu, Daniel E. Spratt, and Melody J. Xu

Subjects
Oncology, Cancer Research, medicine.medical_specialty, Radiation, business.industry, chemistry.chemical_element, medicine.disease, Prostate cancer, Salvage radiation, chemistry, Internal medicine, Psma pet, medicine, Radiology, Nuclear Medicine and imaging, Gallium, business
Published
2017
Full Text
View/download PDF

36. Effect of Ga-68 PSMA PET Imaging on Radiation Treatment Plans for Prostate Cancer

Author

Hao G. Nguyen, Peter R. Carroll, I-Chow Joe Hsu, Lauren Boreta, F.Y. Feng, Mack Roach, Susan Y. Wu, Thomas A. Hope, A. Wu, and Albert J. Chang

Subjects
Oncology, Cancer Research, medicine.medical_specialty, Prostate cancer, Radiation, business.industry, Internal medicine, Psma pet, medicine, Radiology, Nuclear Medicine and imaging, business, medicine.disease
Published
2017
Full Text
View/download PDF

37. A Multi-institutional Phase 2 Trial Assessing Quality of Life (QOL) After Electromagnetic Transponder Guided Prostate Stereotactic Body Radiation Therapy (SBRT)

Author

W.C. Jackson, D.W. Litzenberg, M. Schipper, J. Wei, S.A. Rosenthal, G.C. Chang, E.M. Horwitz, J. Li, J.M. Michalski, H.A. Gay, F.Y. Feng, H.M. Sandler, R.E. Wallace, and D.A. Hamstra

Subjects
Cancer Research, medicine.medical_specialty, Radiation, business.industry, Stereotactic body radiation therapy, Phase (combat), medicine.anatomical_structure, Oncology, Quality of life, Prostate, medicine, Radiology, Nuclear Medicine and imaging, Medical physics, business, Transponder
Published
2015
Full Text
View/download PDF

38. Validation of the Combination Gleason Score as an Independent Favorable Prognostic Factor in GS 7-10 Prostate Cancer Treated With Dose-Escalated Radiation Therapy

Author

W.C. Jackson, J. Chan, A. McNamara, D.R. Wahl, F.Y. Feng, and Daniel A. Hamstra

Subjects
Oncology, Cancer Research, medicine.medical_specialty, Radiation, Prostatectomy, business.industry, medicine.medical_treatment, Cancer, medicine.disease, Radiation therapy, Prostate cancer, medicine.anatomical_structure, Prostate, Internal medicine, Cohort, medicine, Clinical endpoint, Radiology, Nuclear Medicine and imaging, Stage (cooking), business
Abstract

PURPOSE/OBJECTIVE(S) Prognostic factors that alter prostate cancer effect include TNM stage, pre-treatment PSA, Gleason score, and Gleason grade group (2). Of these, Gleason score yields the largest impact on cause-specific survival (CSS) (5). While Gleason score is crucial to predicting outcomes, disparity between biopsy and prostatectomy sample scores is often seen. This can result in Gleason score upgrading (GSU) and downgrading (GSD) at the time of surgery. Phillips et al. explored this phenomenon through combining the lowest and highest Gleason scores at biopsy (ComboGS) and examining how such a factor would impact GSU and prostate cancer specific survival (PCSM). This study aims to validate the Phillips et al. findings via an independent cohort of prostate cancer patients treated with definitive dose-escalated radiation therapy (DE-RT) at a single institution. MATERIALS/METHODS DE-RT was administered to 2,539 men; 687 men had a ComboGS. We utilized univariate and multivariable analysis to evaluate relapse rates and clinical outcomes. To further ascertain the ComboGS prognostic impact, we employed the Cancer of the Prostate Risk Assessment Score (CAPRA) and the modified CAPRA (mCAPRA). Rates of biochemical event-free survival (bEFS) and distant metastasis-free survival (DMFS) were compared across CAPRA scores, with and without modification, and the prognostic value of the CAPRA scores were compared using Harrel's concordance index (C-index) (12). RESULTS ComboGS presence in Gleason 7-10 prostate cancer patients generated improved 10-year biochemical event-free survival (bEFS) from 76.6% to 82.4% (HR 0.75, CI 0.59-0.96, P = 0.021), 10-year distant metastasis-free survival (DMFS) from 89.3% to 93.2% (HR 0.57, CI 0.39-0.85, P = 0.005), 10-year PCSM from 93.9% to 97.4% (HR 0.39, CI 0.21-0.7, P = 0.001) and 10-year overall survival (OS) from 65.7% to 75.6% (HR 0.69, CI 0.57-0.83, P < 0.001). Multivariable analysis also supported that ComboGS is protective for biochemical failure (HR 0.64, CI 0.50-0.83, P < 0.001), distant metastasis (HR 0.42, CI 0.28-0.63, P < 0.001), death from prostate cancer (HR 0.32, CI 0.17-0.58, P < 0.001), and overall mortality (HR 0.65, CI 0.54-0.79, P < 0.001). Additionally, adjusting the CAPRA score for ComboGS decreased the risk of biochemical failure (BF) by nearly 30% (HR = 0.70 [95% CI, 0.55-0.88], P = 0.003) and by 50% (HR = 0.54 [95% CI, 0.37-0.80], P = 0.002) for distant metastasis. CONCLUSION ComboGS is a useful and readily available independent prognostic factor for all clinical endpoints (biochemical failure, distant metastasis, cancer-specific survival and overall survival). Moreover, the ComboGS can be used in conjunction with the extensively validated CAPRA scoring, to better risk stratify patients being treated with definitive DE-RT and possibly de-escalate therapy for some men with ComboGS 7 disease.

Published
2015
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results